A drug in clinical trials as a treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) works with a one-two punch that shuts down triglyc
A drug in clinical trials as a treatment for metabolic dysfunction-associated steatotic liver disease (MASLD) works with a one-two punch that shuts down triglyc
Researchers at UT Southwestern Medical Center have found that individuals who carry a specific form of the gene PNPLA3 have more fat in their livers and a greater risk of developing liver inflammation.